Caribou Biosciences, Inc.
CRBU
$1.44
-$0.10-6.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.04M | 11.20M | 11.16M | 9.30M | 9.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.04M | 11.20M | 11.16M | 9.30M | 9.12M |
| Cost of Revenue | 85.77M | 94.52M | 109.44M | 116.09M | 124.11M |
| Gross Profit | -75.73M | -83.32M | -98.28M | -106.79M | -114.99M |
| SG&A Expenses | 33.74M | 36.25M | 37.91M | 39.82M | 40.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.51M | 130.76M | 147.35M | 155.91M | 164.58M |
| Operating Income | -109.47M | -119.56M | -136.19M | -146.62M | -155.45M |
| Income Before Tax | -103.95M | -133.77M | -148.68M | -157.14M | -164.27M |
| Income Tax Expenses | -550.00K | -550.00K | -550.00K | -9.00K | -9.00K |
| Earnings from Continuing Operations | -103.40 | -133.22 | -148.13 | -157.13 | -164.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.40M | -133.22M | -148.13M | -157.13M | -164.26M |
| EBIT | -109.47M | -119.56M | -136.19M | -146.62M | -155.45M |
| EBITDA | -106.89M | -116.43M | -132.55M | -142.47M | -150.76M |
| EPS Basic | -1.08 | -1.42 | -1.59 | -1.70 | -1.79 |
| Normalized Basic EPS | -0.68 | -0.81 | -0.91 | -0.98 | -1.03 |
| EPS Diluted | -1.08 | -1.42 | -1.59 | -1.70 | -1.79 |
| Normalized Diluted EPS | -0.68 | -0.81 | -0.91 | -0.98 | -1.03 |
| Average Basic Shares Outstanding | 384.68M | 376.72M | 373.54M | 370.16M | 367.33M |
| Average Diluted Shares Outstanding | 384.68M | 376.72M | 373.54M | 370.16M | 367.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |